Focus on Immunotherapies

OCTOBER 26-27, 2018
LIVE SIMULCAST
Systemic anticancer therapies including cytotoxic chemotherapies, targeted therapies, and immunotherapies have resulted in improvements in patient survival. Despite this remarkable success, the majority of patients will develop toxicities of various organ systems, which may impact overall health and activities of daily living, resulting in inconsistent antineoplastic therapy, all of which may affect clinical outcome. Therefore, prevention and management of untoward events is critical for the maintenance of quality of life and the optimization of anticancer therapies.

Target Audience
The target audience includes MDs, PAs, NPs, RNs, Pharmacists, and other professionals involved in the care of cancer patients.

Educational Objectives
• Recognize the clinical presentation, impact on quality of life, and grading of treatment-related adverse events in cancer patients
• Understand mechanisms and interventions to prevent and treat acute and chronic adverse events in cancer patients and survivors
• Discuss procedures and clinical tools to assess treatment-related toxicities in cancer patients

SYMPOSIUM HIGHLIGHTS
• Therapy-related adverse events will affect the majority of patients, resulting in increased cost, inconsistent dosing, and decreased quality of life.
• With increased survival and patients living longer on therapy, adverse events affecting quality of life and clinical outcome command attention.
• This symposium provides up to date information on adverse event mechanisms and management, from specialists in the most commonly affected organ systems.
• Practical strategies to maintain patients’ quality of life and dose intensity will be highlighted for the most frequently occurring events.
Welcome and Introduction

Chemotherapy Induced Peripheral Neuropathy

Nephrotoxicities

Panel Discussion

Nausea and Vomiting

Adjourn

Hypersensitivity Reactions

VTE and Treatment-Related Coagulopathies

Laura Capelli, MD, MHS, MS

Break

Break

Robin Mendelsohn, MD

Dermatologic Toxicities from Cytotoxic

Cardiac Toxicities

Monica Girotra, MD

Immune-Related Neurologic Events

Kathryn Ciccolini, AGANCP-BC, NP

Immune-Related Pulmonary Events

Bianca Santomasso, MD, PhD

Treatment-Related Adverse Event Research

Closing Remarks

Anthony Yu, MD

Rajesh Lalla, DDS, PhD, DABOM

Lunch

Diarrhea and Constipation

Gerald A. Soff, MD

Florian Scotte, MD, PhD

Adverse Event Triage and Acute Evaluations

All Faculty

Mucositis and Stomatitis

All Faculty

Hyperglycemia and Cushing Disease

Charles Loprinzi, MD

Welcome and Introduction:

Douglas Johnson, MD

Korey Jaben, MD

Mario E. Lacouture, MD

Mariana Castells, MD, PhD

Immune-Related GI Adverse Events

Mario E. Lacouture, MD

Treatment-Related Psychiatric and

Immune-Related Rheumatic Disorders

MONERTADOR: Mario E. Lacouture, MD

9:00 AM Welcome and Introduction: Importance of Adverse Events  Mario E. Lacouture, MD

9:15 AM Treatment-Related Adverse Event Research  Florian Lacouture, MD, PhD

9:45 AM Adverse Event Triage and Acute Evaluations  Kathryn Ciccolini, AGANCP-BC, NP

10:00 AM Nausea and Vomiting  Mark Kris, MD

10:25 AM Diarrhea and Constipation  Robin Mendelsohn, MD

10:50 AM Break

11:15 AM Nephrotoxicities  Joannie Lefebvre, MD, FRCPC

11:40 AM VTE and Treatment-Related Coagulopathies  Gerald A. Soff, MD

12:10 PM Panel Discussion  All Faculty

12:30 PM Lunch

MODERATOR:

Session II

Immunotherapy-Related Adverse Events

Friday, October 26

MODERATOR: Mario E. Lacouture, MD

1:30 pm

MODERATOR:

Cytotoxic and Targeted Therapies

1:00 pm

MODERATOR:

Session I

Cytotoxic and Targeted Therapies

11:30 am

MODERATOR:

Immunotherapy-Related Adverse Events

11:00 am

MODERATOR:

Session II

Immunotherapy-Related Adverse Events

9:45 am

MODERATOR:

Cytotoxic and Targeted Therapies

9:15 am

MODERATOR:

Session I

Cytotoxic and Targeted Therapies

8:45 am

MODERATOR:

Immunotherapy-Related Adverse Events

8:15 am

MODERATOR:

Cytotoxic and Targeted Therapies

8:00 am

MODERATOR:

Immunotherapy-Related Adverse Events

7:50 am

MODERATOR:

Cytotoxic and Targeted Therapies

7:30 am

MODERATOR:

Immunotherapy-Related Adverse Events

7:00 am

MODERATOR:

Cytotoxic and Targeted Therapies

6:15 am

MODERATOR:

Immunotherapy-Related Adverse Events

6:00 am

MODERATOR:

Cytotoxic and Targeted Therapies

5:05 pm

MODERATOR:

Cytotoxic and Targeted Therapies

5:00 pm

MODERATOR:

Immunotherapy-Related Adverse Events

4:35 pm

MODERATOR:

Cytotoxic and Targeted Therapies

4:15 pm

MODERATOR:

Immunotherapy-Related Adverse Events

3:15 pm

MODERATOR:

Cytotoxic and Targeted Therapies

3:00 pm

MODERATOR:

Immunotherapy-Related Adverse Events

2:45 pm

MODERATOR:

Cytotoxic and Targeted Therapies

2:30 pm

MODERATOR:

Immunotherapy-Related Adverse Events

2:15 pm

MODERATOR:

Cytotoxic and Targeted Therapies

2:00 pm

MODERATOR:

Immunotherapy-Related Adverse Events

1:45 pm

MODERATOR:

Cytotoxic and Targeted Therapies

1:30 pm

MODERATOR:

Immunotherapy-Related Adverse Events

1:15 pm

MODERATOR:

Cytotoxic and Targeted Therapies

1:00 pm

MODERATOR:

Immunotherapy-Related Adverse Events

All times are Eastern Standard Time (EST).
REGISTRATION

Live Simulcast Rate  $600

Register Online:
mskcc.org/AdverseEvents

Detailed instructions will be emailed to attendees before the course and will include a link to the simulcast. Registration for this simulcast is non-refundable.

- **30% Discounted Rate for MSK Alumni and MSK Cancer Alliance Members:** MSK offers a 30% discounted rate to all MSK Alumni and MSK Alliance members to attend a CME course. Please contact cme@mskcc.org for a promotion code or more information.

- **MSK Staff Registration:** Registration is complimentary for MSK staff. However, you must register online: mskcc.org/AdverseEvents

**ACCREDITATION STATEMENT**
MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**AMA CREDIT DESIGNATION STATEMENT**
MSK designates this live activity for a maximum of **12.50 AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**ABIM MOC RECOGNITION STATEMENT**
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **12.50 Medical Knowledge MOC Points** in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit

**FACULTY DISCLOSURE**
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

**CONTACT**
Memorial Sloan Kettering Cancer Center
Office of Continuing Medical Education
W:  mskcc.org/cme
E:  cme@mskcc.org